Chronic myeloid leukemia, or CML in short, is a blood cancer that begins in the bone marrow's blood-producing cells and spreads into the bloodstream. This type of leukemia accounts for approximately 15% of all adult leukemia cases. Novartis' Gleevec is considered the standard of care for first-line treatment of chronic-phase chronic myeloid leukemia.
Before Gleevec became available, CML patients faced a grim prognosis, with annual survival rates below 20%. The advent of this targeted therapy has led to remarkable improvements in long-term survival, with 10-year survival rates now exceeding 80%, representing a more than fourfold increase in patient longevity. Despite significant advances, there continues to be a substantial unmet medical need for improved therapeutic options in chronic myeloid leukemia treatment.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.